These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
140 related articles for article (PubMed ID: 7702626)
21. Identification of a stop mutation in five Finnish patients suffering from hereditary tyrosinemia type I. St-Louis M; Leclerc B; Laine J; Salo MK; Holmberg C; Tanguay RM Hum Mol Genet; 1994 Jan; 3(1):69-72. PubMed ID: 8162054 [TBL] [Abstract][Full Text] [Related]
22. Congenital erythropoietic porphyria: prolonged high-level expression and correction of the heme biosynthetic defect by retroviral-mediated gene transfer into porphyric and erythroid cells. Kauppinen R; Glass IA; Aizencang G; Astrin KH; Atweh GF; Desnick RJ Mol Genet Metab; 1998 Sep; 65(1):10-7. PubMed ID: 9787090 [TBL] [Abstract][Full Text] [Related]
23. Hepatic stress in hereditary tyrosinemia type 1 (HT1) activates the AKT survival pathway in the fah-/- knockout mice model. Orejuela D; Jorquera R; Bergeron A; Finegold MJ; Tanguay RM J Hepatol; 2008 Feb; 48(2):308-17. PubMed ID: 18093685 [TBL] [Abstract][Full Text] [Related]
24. Adenovirus-mediated gene therapy in a mouse model of hereditary tyrosinemia type I. Overturf K; al-Dhalimy M; Ou CN; Finegold M; Tanguay R; Lieber A; Kay M; Grompe M Hum Gene Ther; 1997 Mar; 8(5):513-21. PubMed ID: 9095403 [TBL] [Abstract][Full Text] [Related]
25. Retrovirus-mediated transfer of the human alpha-L-iduronidase cDNA into human hematopoietic progenitor cells leads to correction in trans of Hurler fibroblasts. Huang MM; Wong A; Yu X; Kakkis E; Kohn DB Gene Ther; 1997 Nov; 4(11):1150-9. PubMed ID: 9425437 [TBL] [Abstract][Full Text] [Related]
26. Two novel FAH gene mutations in a patient with hereditary tyrosinemia type I. Choi HJ; Bang HI; Ki CS; Lee SY; Kim JW; Song J; Shin MR; Lee YW; Lee DH; Park HD Ann Clin Lab Sci; 2014; 44(3):317-23. PubMed ID: 25117105 [TBL] [Abstract][Full Text] [Related]
27. Amelioration of prolidase deficiency in fibroblasts using adenovirus mediated gene transfer. Ikeda K; Tohyama J; Tsujino S; Sato K; Oono T; Arata J; Endo F; Sakuragawa N Jpn J Hum Genet; 1997 Sep; 42(3):401-8. PubMed ID: 12503186 [TBL] [Abstract][Full Text] [Related]
28. Ex vivo hepatic gene therapy of a mouse model of Hereditary Tyrosinemia Type I. Overturf K; Al-Dhalimy M; Manning K; Ou CN; Finegold M; Grompe M Hum Gene Ther; 1998 Feb; 9(3):295-304. PubMed ID: 9508047 [TBL] [Abstract][Full Text] [Related]
29. Hereditary tyrosinemia type I: lack of correlation between clinical findings and amount of immunoreactive fumarylacetoacetase protein. Kvittingen EA; Rootwelt H; van Dam T; van Faassen H; Berger R Pediatr Res; 1992 Jan; 31(1):43-6. PubMed ID: 1594329 [TBL] [Abstract][Full Text] [Related]
30. Structural organization and analysis of the human fumarylacetoacetate hydrolase gene in tyrosinemia type I. Awata H; Endo F; Tanoue A; Kitano A; Nakano Y; Matsuda I Biochim Biophys Acta; 1994 May; 1226(2):168-72. PubMed ID: 8204664 [TBL] [Abstract][Full Text] [Related]
31. Gene expression profiles of homogentisate-treated Fah-/- Hpd-/-mice using DNA microarrays. Tanaka Y; Nakamura K; Matsumoto S; Kimoto Y; Tanoue A; Tsujimoto G; Endo F Mol Genet Metab; 2006 Nov; 89(3):203-9. PubMed ID: 16899383 [TBL] [Abstract][Full Text] [Related]
32. Type I tyrosinemia: lack of immunologically detectable fumarylacetoacetase enzyme protein in tissues and cell extracts. Berger R; Van Faassen H; Taanman JW; De Vries H; Agsteribbe E Pediatr Res; 1987 Oct; 22(4):394-8. PubMed ID: 3317254 [TBL] [Abstract][Full Text] [Related]
33. Enzyme defect in a case of tyrosinemia type I, acute form. Furukawa N; Kinugasa A; Seo T; Ishii T; Ota T; Machida Y; Inoue F; Imashuku S; Kusunoki T; Takamatsu T Pediatr Res; 1984 May; 18(5):463-6. PubMed ID: 6145143 [TBL] [Abstract][Full Text] [Related]
34. The human fumarylacetoacetase gene: characterisation of restriction fragment length polymorphisms and identification of haplotypes in tyrosinemia type 1 and pseudodeficiency. Rootwelt H; Kvittingen EA; Høie K; Agsteribbe E; Hartog M; van Faassen H; Berger R Hum Genet; 1992 May; 89(2):229-33. PubMed ID: 1350265 [TBL] [Abstract][Full Text] [Related]
35. [Sepsis, as the presenting form of hereditary tyrosinemia type I]. Iglesias Niubo J; Riudor Taravilla E; Goma Brufau AR; Civit Colas MA; Suñé Gracia JM; Bertrán Sanges JM; Gallart Catalá A An Esp Pediatr; 1988 Sep; 29(3):235-8. PubMed ID: 3057981 [TBL] [Abstract][Full Text] [Related]
36. The pre- and post-natal diagnosis of tyrosinemia type I and the detection of the carrier state by assay of fumarylacetoacetase. Kvittingen EA; Brodtkorb E Scand J Clin Lab Invest Suppl; 1986; 184():35-40. PubMed ID: 3473612 [TBL] [Abstract][Full Text] [Related]
37. Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Grompe M; Lindstedt S; al-Dhalimy M; Kennaway NG; Papaconstantinou J; Torres-Ramos CA; Ou CN; Finegold M Nat Genet; 1995 Aug; 10(4):453-60. PubMed ID: 7545495 [TBL] [Abstract][Full Text] [Related]
38. Suppression of distant pulmonary metastasis of MDA-MB 435 human breast carcinoma established in mammary fat pads of nude mice by retroviral-mediated TIMP-2 gene transfer. Lee YK; So IS; Lee SC; Lee JH; Lee CW; Kim WM; Park MK; Lee ST; Park DY; Shin DY; Park CU; Kim YS J Gene Med; 2005 Feb; 7(2):145-57. PubMed ID: 15546163 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of dichloroacetate treatment in a murine model of hereditary tyrosinemia type 1. Langlois C; Jorquera R; Finegold M; Shroads AL; Stacpoole PW; Tanguay RM Biochem Pharmacol; 2006 May; 71(11):1648-61. PubMed ID: 16581029 [TBL] [Abstract][Full Text] [Related]
40. Deficiency of fumarylacetoacetase in a patient with hereditary tyrosinemia. Berger R; Smit GP; Stoker-de Vries SA; Duran M; Ketting D; Wadman SK Clin Chim Acta; 1981 Jul; 114(1):37-44. PubMed ID: 7249373 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]